Skip to content

    Laxmi Dental Limited

    LAXMIDENTL
    Healthcare·11 Feb 2026
    Management Summary

    Laxmi Dental reported a 7.1% YoY revenue growth to INR 66 crores in Q3 FY26, driven by strong international lab and scanner sales, despite a challenging macroeconomic environment and softness in domestic segments. The company's EBITDA margin was 10.6%, impacted by US tariffs and a one-time exceptional charge of INR 5.8 crores. Management is optimistic about Q4 FY26 and FY27, citing reduced US tariffs, EU FTA developments, and strategic initiatives in digital dentistry and product innovation.

    Highlights

    5
    • Revenue grew 7.1% YoY to INR 66 crores despite challenging global environment.

    • International lab business delivered robust 25% YoY growth.

    • Scanner sales showed strong 46% YoY growth, reaching INR 6.4 crore.

    • Company is debt-free, leading to significant reduction in finance costs to INR 0.3 crore.

    • US tariffs reduced from 50% to 25%, expected to improve profitability and competitiveness.

    Concerns

    3
    • EBITDA margin impacted by 150 bps due to US tariffs, standing at 10.6%.

    • One-time exceptional item of INR 5.8 crores recorded due to new labor code and accounting standard.

    • Domestic lab and aligner (Bizdent) businesses experienced some softness in Q3 FY26 due to competitive pricing and lower NRI travel.

    What Changed2

    vs Q4 FY26

    Guidance items5 → 8 (+3)Risks discussed5 → 6 (+1)

    Key financials

    Single quarter

    09 metrics
    1. 01Revenue from Operations₹66 Cr+7.1%YoY
    2. 02Gross Profit₹45.9 Cr
    3. 03Gross Profit Margin69.5%
    4. 04Employee Costs₹25.9 Cr+19.2%YoY
    5. 05Other Expenses₹13 Cr

    Segment breakdown

    Dental Lab Business
    10.4% Growth
    International Lab Business
    25% Growth
    Aligner Solution Business
    ₹16.4 Cr Revenue
    Vedia (Aligner Raw Material)
    19.6% Growth
    Scanner Sales
    ₹6.4 Cr Revenue46% Growth
    Kids-e-Dental
    ₹5.9 Cr Revenue7.2% Growth
    List

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Debt

    Net ₹0 crores · 0.0x EBITDA

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    International Business Growth
    20-25%
    Medium
    Revenue
    Domestic Business Growth
    20-25%
    Medium
    Revenue
    Aligner Segment Revenue
    Close to INR 24 crores
    Medium
    Margin
    International Business Margin
    Increase from ~22%
    Medium
    Margin
    Overall EBITDA Margin
    18-20%
    Medium
    Volume
    Domestic Lab & Aligner Business Performance
    Strong quarter
    High
    Other
    ESOP Costs
    Half the impact
    High
    Other
    Kids-e-Dental CE Certification
    Approval
    Medium

    What to watch in Q4 FY26

    5

    US Tariff Impact on EBITDA

    Q4 FY26, Q1 FY27
    Current150 bps impact in Q3 FY26
    TargetHalf the impact in Q4 FY26, further improvement from Q1 FY27

    Why it matters

    Direct impact on profitability and competitiveness in a key international market.

    So I think for this quarter, we should see probably half the impact because today it's already 11th, so one and a half month we have paid 50%, but for the rest one and a half month we will pay 25%. But like you said from Q1FY27, we think this should improve our efforts on the US side.

    Risks & concerns

    6
    RiskSeverity

    Challenging global macroeconomic environment and geopolitical situations

    Impacted Q3 FY26 performance, but company expects to sail through with resilience.Management acknowledged

    medium

    US Tariffs (previously 50%, now 25%)

    Impacted Q3 FY26 EBITDA margin by 150 bps; reduction to 25% is a positive development expected to improve profitability.Management acknowledged

    high

    New labor code and accounting standards

    Resulted in a one-time exceptional item of INR 5.8 crores in Q3 FY26.Management acknowledged

    medium

    Competitive pricing environment in clear aligner business (Bizdent)

    Caused softness in Q3 FY26, but new strategies are expected to lead to normalization and strong Q4 FY26.Management acknowledged

    medium

    Slowdown in domestic lab business due to lower NRI travel

    Contributed to softness in Q3 FY26, but new strategies and January 2026 performance indicate recovery for Q4 FY26.Management acknowledged

    medium

    Resistance to technology adoption among dentists for digital dentistry

    95% of dentists still not using scanners, but company's penetration is high at 79% and growing.Management acknowledged

    low

    Q&A highlights

    8

    “So we had to let go of few customers where the tariff situation could not allow us to give them the pricing that they needed. So that was also one of the reason especially in the US where tariff, even if it's at say 20-25% growth, we could have grown much stronger there if not for the tariff situation.”

    Clarifies that tariffs *did* impact sales volume by making pricing uncompetitive, not just margins, and also mentions lower NRI travel.

    asked by Sanjay Sood

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance Overview

    Laxmi Dental reported a revenue of INR 66 crores in Q3 FY26, marking a 7.1% year-on-year growth compared to INR 61.7 crores in the same period last year. Gross profit margin stood at 69.5%, with EBITDA at INR 7 crores, representing a 10.6% margin. Profit after tax for the quarter was INR 2 crores. The company also noted a significant reduction in finance costs to INR 0.3 crore, down from INR 1.5 crore, as it remains debt-free.

    02

    Impact of US Tariffs and Exceptional Items

    The company's EBITDA margin was impacted by approximately 150 basis points in Q3 FY26 due to the full quarter effect of US tariffs. However, recent developments have seen these tariffs reduced from 50% to 25%, with management expecting about half the impact to reverse in Q4 FY26 and further improvement from Q1 FY27. Additionally, a one-time📎 exceptional item📎 of INR 5.8 crores was recorded due to new labor code requirements and accounting standards.

    03

    Segmental Performance and Strategic Initiatives

    The international lab business demonstrated robust growth of 25% YoY, while scanner sales surged by 46% YoY to INR 6.4 crore. The domestic lab business and the Bizdent aligner solution experienced some softness in Q3, attributed to competitive pricing and lower NRI travel. However, strategic initiatives implemented in Q3 have shown positive impacts in January 2026, with management expecting a strong Q4 FY26 for these segments, targeting aligner segment revenue close to INR 24 crores.

    04

    Digital Dentistry and Market Penetration

    Laxmi Dental's digital penetration at the company level has reached 79%, significantly higher than the overall Indian dental industry's single-digit penetration. Management emphasized the strategic importance of scanners, which saw a 46% YoY growth, in driving future growth and promoting digital dentistry. The company aims to reach a 90% digital penetration threshold, which it views as a pivotal point for fully digital operations.

    05

    Future Outlook and Margin Targets

    Management expressed confidence in achieving 20-25% YoY growth for both international and domestic businesses in FY27, assuming a more stable operating environment. They also target an overall EBITDA margin of 18-20% for FY27, up from the current 10.6%, supported by reduced tariffs and lower ESOP costs (expected to halve from next year). The Kids-e-Dental segment, with 7.2% YoY growth, is awaiting CE certification, which is expected in Q4 FY26, to scale in Europe.

    06

    Competition and Operational Efficiency

    The company acknowledges ongoing competition but believes its integrated approach, including 3D printing and CNC machines, provides a significant advantage over smaller, traditional dental labs that face higher investment and technical barriers to digital adoption. Management highlighted that digital impressions eliminate 30-35% of the process involved in physical impressions, enhancing speed, quality, and margin realization.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.